Literature DB >> 16341040

Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients.

M Nyåkern1, P L Tazzari, C Finelli, C Bosi, M Y Follo, T Grafone, P P Piccaluga, G Martinelli, L Cocco, A M Martelli.   

Abstract

The serine/threonine kinase Akt, a downstream effector of phosphatidylinositol 3-kinase (PI3K), is known to play an important role in antiapoptotic signaling and has been implicated in the aggressiveness of a number of different human cancers including acute myeloid leukemia (AML). The progression of myelodysplastic syndromes (MDSs) to AML is thought to be associated with abrogation of apoptotic control mechanisms. However, little is known about signal transduction pathways which may be involved in enhanced survival of MDS cells. In this report, we have performed immunocytochemical and flow cytometric analysis to evaluate the levels of activated Akt in bone marrow or peripheral blood mononuclear cells from patients diagnosed with MDS. We observed high levels of Ser473 phosphorylated Akt (p-Akt) staining in 90% of the cases (n=22) diagnosed as high-risk MDS, whereas mononuclear cells from normal bone marrow or low-risk MDS patients showed low or absent Ser473 p-Akt staining. Furthermore, all high-risk MDS patients also demonstrated high expression of the Class I PI3K p110delta catalytic subunit and a decreased expression of PTEN. Taken together, our results suggest that Akt activation might be one of the factors contributing to the decreased apoptosis rate observed in patients with high-risk MDS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16341040     DOI: 10.1038/sj.leu.2404057

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  21 in total

Review 1.  Mammalian target of rapamycin as a target in hematological malignancies.

Authors:  Kevin R Kelly; Julie H Rowe; Swaminathan Padmanabhan; Steffan T Nawrocki; Jennifer S Carew
Journal:  Target Oncol       Date:  2011-04-17       Impact factor: 4.493

Review 2.  Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies?

Authors:  Yanan Gao; Chase Y Yuan; Weiping Yuan
Journal:  Stem Cell Investig       Date:  2016-07-22

3.  An mTORC1/2 dual inhibitor, AZD2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells.

Authors:  Yu Mizutani; Aki Inase; Yimamu Maimaitili; Yoshiharu Miyata; Akihito Kitao; Hisayuki Matsumoto; Koji Kawaguchi; Ako Higashime; Hideaki Goto; Keiji Kurata; Kimikazu Yakushijin; Hironobu Minami; Hiroshi Matsuoka
Journal:  Int J Hematol       Date:  2019-07-08       Impact factor: 2.490

4.  Antitumor activity and drug interactions of proteasome inhibitor Bortezomib in human high-risk myelodysplastic syndrome cells.

Authors:  Jian Huang; Ting Ding; Min Yang; Hui Liu; Xin Sun; Jie Jin
Journal:  Int J Hematol       Date:  2011-03-31       Impact factor: 2.490

5.  Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.

Authors:  Michael G Kharas; Rachel Okabe; Jared J Ganis; Maricel Gozo; Tulasi Khandan; Mahnaz Paktinat; D Gary Gilliland; Kira Gritsman
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

6.  Mammalian target of rapamycin activity is required for expansion of CD34+ hematopoietic progenitor cells.

Authors:  Christian R Geest; Fried J Zwartkruis; Edo Vellenga; Paul J Coffer; Miranda Buitenhuis
Journal:  Haematologica       Date:  2009-06-16       Impact factor: 9.941

Review 7.  Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome.

Authors:  Daniella B Kerbauy; H Joachim Deeg
Journal:  Exp Hematol       Date:  2007-11       Impact factor: 3.084

8.  A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia.

Authors:  Steven W Paugh; Barbara S Paugh; Mohamed Rahmani; Dmitri Kapitonov; Jorge A Almenara; Tomasz Kordula; Sheldon Milstien; Jeffrey K Adams; Robert E Zipkin; Steven Grant; Sarah Spiegel
Journal:  Blood       Date:  2008-05-29       Impact factor: 22.113

9.  Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS.

Authors:  Matilde Y Follo; Carlo Finelli; Sara Mongiorgi; Cristina Clissa; Costanza Bosi; Nicoletta Testoni; Francesca Chiarini; Giulia Ramazzotti; Michele Baccarani; Alberto M Martelli; Lucia Manzoli; Giovanni Martinelli; Lucio Cocco
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-10       Impact factor: 11.205

10.  Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome.

Authors:  Wolf C Prall; Akos Czibere; Franck Grall; Dimitrios Spentzos; Ulrich Steidl; Aristoteles Achilles Nikolaus Giagounidis; Andrea Kuendgen; Hasan Otu; Astrid Rong; Towia A Libermann; Ulrich Germing; Norbert Gattermann; Rainer Haas; Manuel Aivado
Journal:  Int J Hematol       Date:  2009-01-20       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.